UNICEF signs supply agreement with Pfizer for oral COVID-19 treatment
NEW YORK/COPENHAGEN, 22 March 2022 – UNICEF has signed a supply agreement with Pfizer for the procurement of up to 4 million treatment courses of the new oral antiviral medicine nirmatrelvir/ritonavir (PAXLOVID™) in 2022.
UNICEF procurement of nirmatrelvir/ritonavir (PAXLOVID™) is dependent on country demand, clinical recommendations and necessary approvals.
In December 2021, the US Food and Drug Administration issued an Emergency Use Authorization for the use of nirmatrelvir/ritonavir (PAXLOVID™) for the treatment of mild to moderate cases of COVID-19. Nirmatrelvir/ritonavir (PAXLOVID™) is currently under assessment by the World Health Organization (WHO).
This agreement will help ensure that low- and middle-income countries (LMICs) have timely access to this novel COVID-19 therapeutic. Supply will be made available for procurement and delivery to 95 LMICs, which includes some upper-middle income countries. UNICEF will work closely with WHO and Access to COVID-19 Tools Accelerator (ACT-A) partners such as The Global Fund and Unitaid to ensure equitable access to nirmatrelvir/ritonavir (PAXLOVID™).
UNICEF continues to work with ACT-A partners and industry to facilitate equitable access to COVID-19 therapeutics.
UNICEF promotes the rights and wellbeing of every child, in everything we do. Together with our partners, we work in 190 countries and territories to translate that commitment into practical action, focusing special effort on reaching the most vulnerable and excluded children, to the benefit of all children, everywhere.
For more information about UNICEF and its work for children, visit https://www.unicef.org/eca/.